WO2019070813A3 - Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder - Google Patents

Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder Download PDF

Info

Publication number
WO2019070813A3
WO2019070813A3 PCT/US2018/054109 US2018054109W WO2019070813A3 WO 2019070813 A3 WO2019070813 A3 WO 2019070813A3 US 2018054109 W US2018054109 W US 2018054109W WO 2019070813 A3 WO2019070813 A3 WO 2019070813A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurological disorder
subject
assessing whether
developing
biomarkers
Prior art date
Application number
PCT/US2018/054109
Other languages
French (fr)
Other versions
WO2019070813A2 (en
Inventor
David Sulzer
Alessandro Sette
Original Assignee
The Trustees Of Columbia University In The City Of New York
The Research Foundation For Mental Hygiene, Inc.
La Jolla Institute For Allergy And Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York, The Research Foundation For Mental Hygiene, Inc., La Jolla Institute For Allergy And Immunology filed Critical The Trustees Of Columbia University In The City Of New York
Publication of WO2019070813A2 publication Critical patent/WO2019070813A2/en
Publication of WO2019070813A3 publication Critical patent/WO2019070813A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides methods for assessing whether a subject is at risk of developing a neurological disorder, diagnosing or confirming whether a subject is afflicted with a neurological disorder, assessing whether PD has progressed in a subject afflicted with PD, assessing whether a neurological disorder is developing in a subject who has been identified as being at risk of developing the neurological disorder, assessing whether a subject afflicted with a neurological disorder is likely to benefit from a therapy, assessing whether a subject afflicted with a neurological disorder has benefited from a therapy, treating a subject afflicted with a neurological disorder, and prophylactically treating a subject who has been identified as being at risk of developing a neurological disorder. The present invention also provides epitopes, compounds and compositions relating to these methods.
PCT/US2018/054109 2017-10-03 2018-10-03 Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder WO2019070813A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762567723P 2017-10-03 2017-10-03
US62/567,723 2017-10-03

Publications (2)

Publication Number Publication Date
WO2019070813A2 WO2019070813A2 (en) 2019-04-11
WO2019070813A3 true WO2019070813A3 (en) 2020-03-19

Family

ID=65994286

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/054109 WO2019070813A2 (en) 2017-10-03 2018-10-03 Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder

Country Status (1)

Country Link
WO (1) WO2019070813A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3942026A1 (en) * 2019-03-22 2022-01-26 Université de Paris New inhibitors of lrrk2/pp1 interaction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
WO2015157117A2 (en) * 2014-04-09 2015-10-15 The Trustees Of Columbia University In The City Of New York Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
WO2015157117A2 (en) * 2014-04-09 2015-10-15 The Trustees Of Columbia University In The City Of New York Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder

Also Published As

Publication number Publication date
WO2019070813A2 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
WO2015157117A3 (en) Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder
NZ746901A (en) Bicyclic compounds for diagnosis and therapy
NZ706337A (en) Antibodies recognizing alpha-synuclein
WO2018089693A3 (en) Methods for determining and monitoring gastrointestinal inflammation
MX356800B (en) Humanized tau antibody.
WO2014124334A3 (en) Transthyretin antibodies and uses thereof
MY181969A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
MX2017016134A (en) Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease.
WO2016012285A3 (en) Method
EA201890313A1 (en) HUMANIZED ANTIBODIES TO THE PIE-GLUTATIVE BETA-AMYLOID OPTION
TN2017000072A1 (en) Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor
MX2020001193A (en) Methods for determining dpp3 and therapeutic methods.
WO2015168602A3 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
WO2019098763A3 (en) ANTIBODIES TO α-SYNUCLEIN AND USES THEREOF
PH12018500578A1 (en) Methods of treating inflammatory diseases
IL273169A (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
EA201790211A1 (en) METHOD FOR PREDICTING THE RESULTS OF THE TREATMENT OF AFLIBERCEPT PATIENTS PREFERREDLY SUFFERING FROM CANCER
NZ729773A (en) Biomarkers for disease progression in melanoma
WO2015157678A3 (en) Use of micro-ribonucleic acid (mirna) to diagnose transplant rejection and tolerance of immunosuppression therapy
WO2019070813A3 (en) Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder
WO2020209988A3 (en) Diverse marker panel for ptsd diagnosis and treatment
IL289592A (en) Methods for diagnosing the effectiveness of anti-tumor treatment
WO2018022604A3 (en) Methods of diagnosing and treating alzheimer's disease with s-equol
PH12021550055A1 (en) Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18864351

Country of ref document: EP

Kind code of ref document: A2